To Increase Patient Access

May 17, 2023

Imvax Immunotherapy Clinical Study


We wanted to make you aware of a new Phase 2b Clinical Study with a Combination Immunotherapy for Newly Diagnosed Patients with Glioblastoma (GBM).

Imvax is a clinical-stage biotechnology company with a unique platform technology, Goldspire™, focused on delivering personalized, whole tumor-derived immunotherapies across a range of solid tumors. Imvax’s most advanced program, IGV-001, is currently being evaluated in a Phase 2b clinical trial in newly diagnosed glioblastoma patients (NCT04485949). Imvax’s portfolio also includes several other programs designed to stimulate a patient’s immune system against the entire antigen signature of their tumor. Imvax is headquartered in Philadelphia, PA.

For additional information on the Imvax Immunotherapy Clinical Study, please visit and follow @imvax_inc on Twitter and LinkedIn, contact Madhavi Diwanji at 267-900-4110 or at  OR please contact, fill out our short “Advocacy & Patient Inquiry Form” on our website, or call EBCI’s Program & Trial/Study Manager at 425-436-8688 or email us at  We are here to help.


Dellann Elliott Mydland
President & Board Chair

The EndBrainCancer Initiative | Chris Elliott Fund


Enhancing patient outcomes by expanding FDA-approved treatment modalities and fueling research in the pharma/bio/life sciences, device & diagnostic industries and by closing the existing GAP from initial diagnosis to IMMEDIATE AND EXPANDED ACCESS to specialists, researchers, advanced & innovative treatments, clinical trials and critical care with the ultimate goal of improving patient outcomes through updating and improving WHO & NCCN Guidelines and clinical practices related to Standard of Care for brain cancer patients.

TAX ID:26-2185614
corporate partners
upcoming events
About us
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram